

Digital Data Flow

Last Updated: 13th June 2023

This initiative aims to move the drug development process from a current state of manual, study start-up asset creation (i.e. Case Report Forms, Procedure Manuals, Statistical Analysis Plans, and Schedule of Activities) to a future state of fully automated, dynamic, study start-up readiness via an open-sourced, vendor-agnostic technical solution that will reduce cycle times and improve data quality for sponsors, third-party providers, sites and regulators.

Links

- Transcelerate Digital Data Flow page
 - <https://www.transceleratebiopharmainc.com/initiatives/digital-data-flow/>
- CDISC DDF Page
 - <https://www.cdisc.org/ddf>
- CDISC Github
 - <https://github.com/cdisc-org/DDF-RA>

Main Elements

- Reference Architecture (CDISC)
 - Unified Study Definitions Model (USDM)
 - Controlled Terminology (CT)
 - Application Programming Interface (API)
 - Implementation Guide (IG)
- Reference Implementation (Accenture), the Study Definitions Repository (SDR)



CDISC's Activities on DDF, Benefits for the Community, and Looking Ahead

Presented by D Iberson-Hurst
Partner d4k & CDISC DDF Product Owner

Project Background (see slide deck above)


- Phase 1 -> USDM V1
- Phase 2 -> USDM V2
- **At GGG Approval Stage**
- **To Be Published July 2023**

MIRO Board Status

- Used for technical run throughs
- Staging zone for Implementation Guide content
- **Status: Informational. Updated regularly**


Phase One and Two

CDISC DDF Phase One v Two



CDISC DDF Phase One

July, 2021 – July 2022



V1.0 Provisional
<https://www.cdisc.org/ddf>


Phase One & Two

- Small slide deck re Phase One and Two

Changes Between Phase One and Two

- Addition of timing within studies to schedule activities accurately
- Addition of Biomedical Concepts (BCs)
- Improvements to CT handling
- Additional attributes in some classes to support TCB CPT

UML Model



- The normative Unified Study Definitions Model (USDM)
- Available from Github

- CDISC Github
 - <https://github.com/cdisc-org/DDF-RA/tree/main/Deliverables/UML>

Controlled Terminology

A	B	C	D	E	F	G	H	I
Row #	Entity Name	Role	Logical Data Model Name	NCI C-code	CT Item Preferred Name	Synonym(s)	Definition	Has Value List
12	StudyProtocolVersion	Entity	StudyProtocolVersion	C93490	Study Protocol Version		A plan at a particular point in time for a formal investigation to assess the utility, impact, pharmacological, physiological, and/or psychological effects of a particular treatment, procedure, drug, device, biologic, food product, cosmetic, care plan, or subject characteristic. (BRIDG)	N
13								
14	StudyProtocolVersion	Attribute	briefTitle	C132345	Brief Protocol Title	Abbreviated Protocol Title	The short descriptive name for the protocol.	N
15	StudyProtocolVersion	Attribute	officialTitle	C132346	Official Protocol Title		The formal descriptive name for the protocol.	N
16	StudyProtocolVersion	Attribute	publicTitle	C94105	Public Protocol Title		The descriptive name of the protocol that is intended for the lay public, written in easily understood language.	N
17	StudyProtocolVersion	Attribute	scientificTitle	C132350	Scientific Protocol Title		A more extensive descriptive name of the protocol that is intended for medical professionals, written using medical and scientific language.	N
18	StudyProtocolVersion	Attribute	protocolVersion	C93490	Study Protocol Version		A plan at a particular point in time for a formal investigation to assess the utility, impact, pharmacological, physiological, and/or psychological effects of a particular treatment, procedure, drug, device, biologic, food product, cosmetic, care plan, or subject characteristic. (BRIDG)	N
19	StudyProtocolVersion	Attribute	protocolAmendment	C132347	Study Protocol Amendment		A written description of a change(s) to, or formal clarification of, a protocol. (ICH E6)	N
20	StudyProtocolVersion	Attribute	protocolEffectiveDate	C188817	Study Protocol Amendment Effective Date		The date and time specifying when the protocol amendment takes effect or becomes operative.	N
21	StudyProtocolVersion	Attribute	protocolStatus	C188818	Protocol Status		A condition of the protocol at a point in time with respect to its state of readiness for implementation.	Y (C188723)

CT

- Provides a list of all classes and attributes
- Provides a definition
- Provides CT references
- Available from Github
- IG now has a UML and CT "merge" summary

Links

- CDISC Github
 - <https://github.com/cdisc-org/DDF-RA/tree/main/Deliverables/CT>

API

Simple API for DDF 1.7 Provisional (0.31) OAS3

/openapi.json

A simple TransCelerate Digital Data Flow (DDF) Study Definitions Repository API.

Production Routes that form the production specification.

POST	<code>/v1/studyDefinitions</code>	Create a study
GET	<code>/v1/studyDefinitions/{uuid}</code>	Return a study
PUT	<code>/v1/studyDefinitions/{uuid}</code>	Update a study
GET	<code>/v1/studyDefinitions/{uuid}/history</code>	Returns the study history
GET	<code>/v1/studyDesigns</code>	Study designs for a study

API

- OpenAPI specification
- Bulk API
- Available from Github

Links

- CDISC Github
 - <https://github.com/cdisc-org/DDF-RA/tree/main/Deliverables/API>

Implementation Guide

Implementation Guide

- Note that the IG is version 2
- There was no IG with version 1 of the USDM
- Available from Github

Links

- CDISC Github
 - <https://github.com/cdisc-org/DDF-RA/tree/main/Deliverables/IG>

CDISC USDM-IG (Version 2.0 Draft for Internal Review)



**Unified Study Definitions Model
Implementation Guide (USDM-IG)**

Version 2.0 (Draft for Internal Review)

Prepared by the
DDF Team

Notes to Readers

- This is the draft version 2.0 of the Unified Study Definitions Model Implementation Guide (USDM-IG v2.0). It is intended for Internal Review only and is not a final version.

Revision History

Date	Version
2023-03-08	2.0 Draft for Internal Review


© 2023 Clinical Data Interchange Standards Consortium, Inc. All rights reserved.

© 2023 Clinical Data Interchange Standards Consortium, Inc. All rights reserved.
Draft for Internal Review

Page 1
[Publish Date]

Overview

DDF Model
13th April 2023
Phase 2 Sprint 11. End of internal review, pre public review.
For Information Only




Main Areas

- Study
 - Protocol Version
 - Study Identifiers
- Study Design
 - Arms, Epochs ...
 - Study Timing
 - Biomedical Concepts
 - Study Populations
 - Study Objectives & Endpoints
 - Study Estimands
 - Interventions
 - Indications
- Utility
 - CT References

"Green Blob" Diagram

- Not Normative
- Informative view of the model
- Used to discuss ideas before putting into normative UML
- Used as a cross-check of normative deliverables at end of sprints





AliasCode and Code

- Code is a standard code reference
 - CDISC CT
 - All other CT
- AliasCode is a mechanism to align a CDISC Code with codes from other CT
 - One standard (CDISC) code
 - Many alternatives

AliasCode and Code

```
{
  "aliasCodeId": "id_123",
  "standardCode": {
    "codeId": "code_29",
    "code": "C25299",
    "codeSystem": "http://www.cdisc.org",
    "codeSystemVersion": "2022-03-25",
    "decode": "Diastolic Blood Pressure"
  },
  "standardCodeAliases": [
    {
      "codeId": "code_30",
      "code": "8462-4",
      "codeSystem": "http://loinc.org/",
      "codeSystemVersion": "2022-03-25",
      "decode": "Diastolic Blood Pressure"
    },
    {
      "codeId": "code_31",
      "code": "271650006",
      "codeSystem": "SNOMED-CT",
      "codeSystemVersion": "2003",
      "decode": "Diastolic Blood Pressure"
    },
    {
      "codeId": "code_32",
      "code": "4154790",
      "codeSystem": "OHSDI",
      "codeSystemVersion": "",
      "decode": "Diastolic Blood Pressure"
    }
  ]
}
```





Study

- Root of the whole model
- One study links to many study designs
- Study also links to
 - identifiers
 - protocol versions


Instance Identifiers

- Study has a UUID (allocated by the SDR)
- All other objects have internal ids that should be unique across the study, used for cross-references
- See **red** in example

Study

```
{
  "studyId": <UUID HERE>,
  "studyTitle": "Small Simple Test Study (SSTS)",
  "studyVersion": "1",
  "studyType": {
    "codeId": "code_11",
    "code": "C98388",
    "codeSystem": "http://www.cdisc.org",
    "codeSystemVersion": "2022-03-25",
    "decode": "Interventional Study"
  },
  "studyPhase": {
    "codeId": "code_10",
    "code": "C49686",
    "codeSystem": "http://www.cdisc.org",
    "codeSystemVersion": "2022-03-25",
    "decode": "Phase IIa Trial"
  },
  "businessTherapeuticAreas": [
    {
      "codeId": "code_34",
      "code": "12345",
      "codeSystem": "Sponsor",
      "codeSystemVersion": "2022",
      "decode": "Business Unit A"
    }
  ],
  "studyIdentifiers": [],
  "studyProtocolVersions": [],
  "studyDesigns": [],
  "studyRationale": "Demonstration",
  "studyAcronym": "SSTS"
}
```

studyProtocolVersions 1:0..*




Business Therapeutic Area

- Sponsor requested. More for downstream processes
- Not the same as StudyDesign therapeuticAreas attribute

One Study, Many Study Designs


- USDM allows for many study designs within a single study
- This accommodates master, umbrella studies etc.



Study Identifiers

Study Identifiers

- Multiple identifiers permitted, various types
 - Sponsor
 - Registry
 - Regulatory Authority
- Should have a Sponsor Id
- Should only have one Sponsor Id
- Note the country code (ISO 3166-1)





```
{
    "studyIdentifierId": "study_identifier_id_3",
    "studyIdentifier": "ACME-5678",
    "studyIdentifierScope": {
        "organizationId": "organization_1",
        "organisationIdentifierScheme": "DUNS",
        "organisationIdentifier": "123456789",
        "organisationName": "ACME Pharma",
        "organisationType": {
            "codeId": "code_13",
            "code": "C70793",
            "codeSystem": "http://www.cdisc.org",
            "codeSystemVersion": "2022-03-25",
            "decode": "Clinical Study Sponsor"
        },
        "organizationLegalAddress": {
            "text": "123",
            "line": "fake street",
            "city": "some town",
            "district": "district 19",
            "state": "TX",
            "postalCode": "12345",
            "country": {
                "codeId": "code_15",
                "code": "USA",
                "codeSystem": "ISO 3166 1 alpha3",
                "codeSystemVersion": "2020-08",
                "decode": "United States of America"
            }
        }
    }
}
```


Protocol Version

Protocol


- Links the Study to the protocol version
- With DDF the existing protocol "document", e.g. MS Word, has been split into
 - a document
 - an electronic design (DDF USDM)
- Need to link which design is valid with which version of the document



Protocol and Study Versions



```
"studyProtocolVersions": [
  {
    "briefTitle": "COVACTA",
    "officialTitle": "A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia",
    "publicTitle": "",
    "scientificTitle": "",
    "protocolVersion": "3",
    "protocolAmendment": null,
    "protocolEffectiveDate": "2020-06-11",
    "protocolStatus": {
      "code": "C85255",
      "codeSystem": "http://www.cdisc.org",
      "codeSystemVersion": "2022-03-25",
      "decode": "Draft"
    }
  }
]
```




Study Design

Study Design


- Root of a single design
- Links all the pieces

Therapeutic Areas

Dictionary / Terminology Name	URL
EUDRACT	https://eudract.ema.europa.eu/docs/technical/EUDRACT_EudraCT_Pick_Lists_and_coded_values_v1_0.xls
ICD-10	https://www.icd10data.com/ICD10CM/Codes
MEDORA	https://www.medora.org/
MeSH	https://www.ncbi.nlm.nih.gov/mesh/
NCI Thesaurus	https://cti.nci.nih.gov/ncitbrowser/
SNOMEDCT	https://www.nlm.nih.gov/healthit/snomedct/index.html
US FDA	https://www.fda.gov/drugs/development-resources/spectrum-diseasesconditions




```
{
  "studyDesignId": "study_design_1",
  "studyDesignName": "Study Design",
  "studyDesignDescription": "foobar",
  "trialIntentTypes": [
    {
      "codeId": "code_24",
      "code": "C15714",
      "codeSystem": "http://www.cdisc.org",
      "codeSystemVersion": "2022-03-25",
      "decode": "Basic Research"
    }
  ],
  "trialType": [
    {
      "codeId": "code_25",
      "code": "C158288",
      "codeSystem": "http://www.cdisc.org",
      "codeSystemVersion": "2022-03-25",
      "decode": "Biosimilarity Study"
    },
    {
      "codeId": "code_26",
      "code": "C49667",
      "codeSystem": "http://www.cdisc.org",
      "codeSystemVersion": "2022-03-25",
      "decode": "Efficacy Study"
    }
  ],
  "interventionModel": {
    "codeId": "code_27",
    "code": "C82639",
    "codeSystem": "http://www.cdisc.org",
    "codeSystemVersion": "2022-03-25",
    "decode": "Parallel Study"
  },
  ...
  >>>
}
```




Study Populations


populationDescription (C70834): string
plannedNumberOfParticipants (C49692): integer
plannedMinimumAgeOfParticipants (C49694) : string
plannedMaximumAgeOfParticipants (C49693) : string
plannedSexOfParticipants (C49696): List(Code) (C66732)



```
"studyStudyDesignPopulations": [  
  {  
    "studyDesignPopulationId": "population_1",  
    "populationDescription": "Population 1",  
    "plannedNumberOfParticipants": 100,  
    "plannedMaximumAgeOfParticipants": "80 years",  
    "plannedMinimumAgeOfParticipants": "18 years",  
    "plannedSexOfParticipants": []  
  }  
]
```




Study Objectives and Endpoints




```

"studyObjectives": [
  {
    "objectiveDesc": "Evaluate sensitivity index from baseline to end of study (16 weeks)",
    "objectiveLevel": {
      "code": "C85826",
      "codeSystem": "http://www.cdisc.org",
      "codeSystemVersion": "2022-03-25",
      "decode": "Trial Primary Objective"
    },
    "objectiveEndpoints": [
      {
        "endpointDesc": "Survival rate after cycle 8 of treatment",
        "endpointPurposeDesc": "EFFICACY",
        "endpointLevel": {
          "code": "C94496",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2022-03-25",
          "decode": "Primary Endpoint"
        }
      }
    ]
  }
]


```




Interventions




```
"studyInvestigationalInterventions": [  
  {  
    "codes": [  
      {  
        "code": "XX031ZA",  
        "codeSystem": "ATC",  
        "codeSystemVersion": "2021",  
        "decode": "SubstX"  
      }  
    ],  
    "interventionDesc": "Treatment with substX"  
  }  
]
```




Indications



```
"studyIndications": [
  {
    "codes": [
      {
        "code": "E11",
        "codeSystem": "ICD-10-CM",
        "codeSystemVersion": "10",
        "decode": "Type 2 diabetes mellitus"
      },
      {
        "code": "44054006",
        "codeSystem": "SNOMED",
        "codeSystemVersion": "2022",
        "decode": "Diabetes mellitus type 2 (disorder)"
      }
    ],
    "indicationDesc": "Diabetes Type II"
  },
  {
    "codes": [
      {
        "code": "E10",
        "codeSystem": "ICD-10-CM",
        "codeSystemVersion": "10",
        "decode": "Type 1 diabetes mellitus"
      },
      {
        "code": "44635009",
        "codeSystem": "SNOMED",
        "codeSystemVersion": "2022",
        "decode": "Diabetes mellitus type 1 (disorder)"
      }
    ],
    "indicationDesc": "Diabetes Type I"
  }
]
```




Study Estimands



```


"studyEstimands": [
  {
    "estimandId": "Estimand_1",
    "summaryMeasure": "Survival of all patients",
    "analysisPopulation": {
      "analysisPopulationId": "AnalysisPopulation_1",
      "populationDescription": "ITT"
    },
    "treatment": "InvestigationalIntervention_2",
    "variableOfInterest": "Endpoint_1",
    "intercurrentEvents": [
      {
        "intercurrentEventId": "IntercurrentEvent_1",
        "intercurrentEventName": "termination",
        "intercurrentEventDescription": "IC Event Description",
        "intercurrentEventStrategy": "Patients with out of range lab values before dosing will be excluded"
      }
    ]
  }
]
  
```



Arms, Epoch etc

High Level Study Design

- Arms & Epochs
- Cells
- Elements
- Encounters (Visits)
- Entry and Exit Rules
- Can be used as a start of SDTM Trial Design Domain population
- Also T domains can be imported to build a study design "framework"



```

"studyCellId": "study_cell_1",
"studyArm": {
  "studyArmId": "study_arm_id_1",
  "studyArmName": "Placebo",
  "studyArmDescription": "The Placebo Arm",
  "studyArmType": {
    "codeId": "code_20",
    "code": "C174268",
    "codeSystem": "http://www.cdisc.org",
    "codeSystemVersion": "2022-03-25",
    "decode": "Placebo Control Arm"
  },
  "studyArmDataOriginDescription": "Captured subject data",
  "studyArmDataOriginType": {
    "codeId": "code_18",
    "code": "C6574y",
    "codeSystem": "http://www.cdisc.org",
    "codeSystemVersion": "1",
    "decode": "SUBJECT DATA"
  }
},
"studyEpoch": {
  "studyEpochId": "study_epoch_data_id_1",
  "studyEpochName": "Run In",
  "studyEpochDescription": "The run in",
  "studyEpochType": {
    "codeId": "code_21",
    "code": "C98779",
    "codeSystem": "http://www.cdisc.org",
    "codeSystemVersion": "2022-03-25",
    "decode": "Run-in Period"
  }
}
...


```

Trial Summary Domain

Trial Summary (TS) Domain

- Initial mapping
- In the IG


Code	CDISC Submission Value	CDISC Synonym(s)	CDISC Definition	NCI Preferred Term	USDM Entity Name	USDM Role	USDM Item Name
C101302	THERAREA	Therapeutic Area	A knowledge field that focuses on research and development of specific treatments for diseases and pathologic findings, as well as prevention of conditions that negatively impact the health of an individual. (NCI)	Therapeutic Area	StudyDesign	Attribute	therapeuticAreas
C112038	INDIC	Trial Disease/Condition Indication; Trial Disease/Condition Indication Description	The textual representation of the condition, disease or disorder that the clinical trial is intended to investigate or address.	Trial Indication	Indication	Entity	Indication
C112038	INDIC	Trial Disease/Condition Indication; Trial Disease/Condition Indication Description	The textual representation of the condition, disease or disorder that the clinical trial is intended to investigate or address.	Trial Indication	Indication	Attribute	indicationDescription
C142175	STYPE	Study Type; Study Type Classification	The nature of the investigation for which study information is being collected. (After clinicaltrials.gov)	Study Type	Study	Attribute	studyType
C48281	TPHASE	Trial Phase; Trial Phase Classification	A step in the clinical research and development of a therapy from initial clinical trials to post-approval studies. NOTE: Clinical trials are generally categorized into four (sometimes five) phases. A therapeutic intervention may be evaluated in two or more phases simultaneously in different trials, and some trials may overlap two different phases. [21 CFR section 312.21; After ICH Topic E8 NOTE FOR GUIDANCE ON GENERAL CONSIDERATIONS FOR CLINICAL TRIALS, CPMP/ICH/291/95 March 1998]	Trial Phase	Study	Attribute	studyPhase
C49652	TINDTP	Trial Intent Type	The planned purpose of the therapy, device, or agent under study in the clinical trial.	Clinical Study by Intent	StudyDesign	Attribute	trialIntentType
C49658	TBLIND	Study Blinding Design; Study Blinding Schema; Study Masking Design; Trial Blinding Design; Trial Blinding Schema; Trial Masking Design	The type of experimental design used to describe the level of awareness of the study subjects and/ or study personnel as it relates to the respective intervention(s) or assessments being observed, received or administered.	Trial Blinding Schema	StudyDesign	Attribute	studyDesignBlindingSchema
C49660	TTYPE	Trial Scope; Trial Type	The nature of the interventional study for which information is being collected.	Trial Type	StudyDesign	Attribute	trialType
C49692	PLANSUB	Anticipated Enrollment; Planned Enrollment; Planned Number of Subjects; Target Enrollment	The planned number of subjects to be entered in a clinical trial. (NCI)	Planned Subject Number	StudyDesignPopulation	Attribute	plannedNumberOfParticipants
C49693	AGEMIN	Planned Minimum Age of Subjects	The anticipated minimum age of the subjects to be entered in a clinical trial. (NCI)	Planned Minimum Age of Subjects	StudyDesignPopulation	Attribute	plannedMinimumAgeOfParticipants
C49694	AGEMAX	Planned Maximum Age of Subjects	The anticipated maximum age of the subjects to be entered in a clinical trial. (NCI)	Planned Maximum Age of Subjects	StudyDesignPopulation	Attribute	plannedMaximumAgeOfParticipants
C49696	SEXPOP	Sex of Participants	The specific sex, either male, female, or mixed of the subject group being studied. (NCI)	Sex of Study Group	StudyDesignPopulation	Attribute	plannedSexOfParticipants
C49802	TITLE	Official Study Title; Study Title; Trial Title	The sponsor-defined name of the clinical study.	Trial Title	Study	Attribute	studyTitle
C98746	INTMODEL	Intervention Model	The general design of the strategy for assigning interventions to participants in a clinical study. (clinicaltrials.gov)	Intervention Model	StudyDesign	Attribute	interventionModel
C70793	SPONSOR	Clinical Study Sponsor; Sponsor; Study Sponsor	An individual, company, institution, or organization that takes responsibility for the initiation, management, and/or financing of a clinical study. [After ICH E6, WHO, 21 CFR 50.3 (e), and after IDMP]	Clinical Study Sponsor	Organization	Valid Value	Valid Value Set for Attribute organizationType
C85826	OBJPRIM	Study Primary Objective; Trial Primary Objective	A principle objective of the study.	Trial Primary Objective	Objective	Valid Value	Valid Value Set for Attribute objectiveLevel
C85827	OBJSEC	Study Secondary Objective; Trial Secondary Objective	An auxiliary objective of the study.	Trial Secondary Objective	Objective	Valid Value	Valid Value Set for Attribute objectiveLevel




Activities, Encounters & "Glue"

Linking Encounters with Activities

- Scheduled Activity Instance links encounters with Activities
- Timing also provided by linking Scheduled Activity Instance to Timing
- Activity links onto Procedures and BCs
- Important piece is the Activity <-> "timing" <-> Encounter linkage




Procedures




Procedures

- Linked from activities with multiple procedures per activity
- Name and description added during internal review
- Can be conditional with condition expressed as text

```
{  
  "procedureId": "Procedure_2",  
  "procedureType": "XXX",  
  "procedureName": "Test9",  
  "procedureDescription": "Test Nine",  
  "procedureCode": {  
    "codeId": "Code_7",  
    "code": "12345679",  
    "codeSystem": "SNOMED",  
    "codeSystemVersion": "January 31, 2018",  
    "decode": "Test"  
  },  
  "procedureIsConditional": true,  
  "procedureIsConditionalReason": "Only do it they have man flu"  
}
```




Encounters



Encounters

- Definition of an encounter
- Cross referenced from Epochs
- References timing to detail the encounter window
- Note encounter type, currently only value is "Visit"


```
{  
  "encounterId": "Encounter_1",  
  "encounterName": "Screening",  
  "encounterDescription": "Screening encounter",  
  "previousEncounterId": null,  
  "nextEncounterId": "Encounter_2",  
  "encounterType": {  
    "codeId": "Code_13",  
    "code": "C25716",  
    "codeSystem": "http://www.cdisc.org",  
    "codeSystemVersion": "2022-12-16",  
    "decode": "Visit"  
  },  
  "encounterEnvironmentalSetting": {  
    "codeId": "Code_14",  
    "code": "C51282",  
    "codeSystem": "http://www.cdisc.org",  
    "codeSystemVersion": "2022-12-16",  
    "decode": "Clinic"  
  },  
  "encounterContactModes": [],  
  "transitionStartRule": {  
    "transitionRuleId": "TransitionRule_1",  
    "transitionRuleDescription": "Subject identified"  
  },  
  "transitionEndRule": {  
    "transitionRuleId": "TransitionRule_2",  
    "transitionRuleDescription": "IEs passed"  
  },  
  "encounterScheduledAtTimingId": null  
}
```



Biomedical Concepts

- Allows for
 - Single BC
 - Hierarchy of BCs
 - Surrogate BCs
- Based on CDISC BC Model
- See example of simple BC to the right

Biomedical Concepts I





Slide Deck

- Sets the scene for BCs
- Used several times to provide the background around BCs

Biomedical Concepts II

View of an CDISC API Instance

- Image is a little old now but useful if you are not familiar with the idea of BCs
- Note
 - Central note and the multiple "data concept" or "property" nodes
 - Code responses or definition, e.g.
 - identification is a single code
 - units has multiple codes
- USDM BCs have three levels, see model below



Biomedical Concepts III

Github Example

[Full JSON Examples](#), see example

```
---
BiomedicalConcept:
  bcName: Diastolic Blood Pressure
  bcConceptId:
    standardCode:
      code: C25299
      codeSystem: http://www.cdisc.org
      codeSystemVersion: "2022-03-25"
      decode: Diastolic Blood Pressure
    standardCodeAliases:
      -
        code: 8462-4
        codeSystem: http://loinc.org/
        codeSystemVersion: "2022-03-25"
        decode: Diastolic Blood Pressure
      -
        code: 271650006
        codeSystem: SNOMED-CT
        codeSystemVersion: "2003"
        decode: Diastolic blood pressure
      -
        code: 4154790
        codeSystem: OHSDI
        codeSystemVersion:
        decode: Diastolic blood pressure
      -
    bcSynonyms:
      -
        - DIABP
        - DIA BP
        - Blood pressure diastolic
        ...
    bcProperties:
      -
        ...

```


bcProperties:

```
  bcPropertyName: Vital Signs Result
  bcPropertyEnabled: true
  bcPropertyRequired: true
  bcPropertyDataType: integer
  bcPropertyConceptId:
    code: C173522
    codeSystem: http://www.cdisc.org
    codeSystemVersion: "2022-03-25"
    decode: Vital Signs Result
  bcPropertyResponseCodes: []

  bcPropertyName: Unit of Pressure
  bcPropertyEnabled: true
  bcPropertyRequired: true
  bcPropertyDataType: string
  bcPropertyConceptId:
    code: C49669
    codeSystem: http://www.cdisc.org
    codeSystemVersion: "2022-03-25"
    decode: Unit of Pressure
  bcPropertyResponseCodes:

  responseCodeEnabled: true
  code:
    code: C49670
    codeSystem: http://www.cdisc.org
    codeSystemVersion: "2022-03-25"
    decode: mmHg



  responseCodeEnabled: true
  code:
    code: C42547
    codeSystem: http://www.cdisc.org
    codeSystemVersion: "2022-03-25"
    decode: Pascal
```



Study Design and Timing

"Timepoints"

- "Timepoints" was a label given to this area on the DDF project just for easy identification of an area of work.
- It is all about study timing



DDF, USDM, Study Design & "Timepoints"

Dave Iberson-Hurst

Version 5
14th February 2023



Slide Deck

- Outlines requirements (slides 7-26)
 - Complex timing
 - Branching
 - Cycles
- Slides 28-44 provide "instance" examples to explain the ideas
- Things have moved on since the slide set was written
 - For example, class naming has changed
 - Still useful for overall concept

Timeline

Basics

- Based upon a “timeline” that uses
 - Entry and Exit
 - Conditions
 - Activity Instances
 - Condition Instances
 - Timing
- Activity Instances are linked by Timing information to position the instances in the timeline
- Linked to encounters, activities as per the current USDM
- Timelines can be referenced and reused


Github Example

See JSON examples
[main branch](#)
[v14.2 branch](#)

v14.2 Branch
is "work in progress",
fixing issues

A **ScheduledActivityInstance** Example.
Colour coding to match diagram

```
{  
  ...  
  {  
    "scheduledInstanceId": "ScheduledActivityInstance_1",  
    "scheduledInstanceType": "ACTIVITY",  
    "scheduleTimelineExitId": null,  
    "scheduledInstanceTimings": [...],  
    "scheduledInstanceTimelineId": null,  
    "defaultConditionId": "ScheduledActivityInstance_2",  
    "epochId": "StudyEpoch_1",  
    "activityIds": [ ... ],  
    "scheduledActivityInstanceEncounterId": "Encounter_1"  
  },  
  ...  
}
```






Timing

Basics

- Two types of relationship
 - Anchor - A fixed point
 - Before or After - A relative point
- Window can be defined
- Descriptive and coded timing values
- Coded values are ISO8601 Durations

```
{  
    "timingId": "Timing_3",  
    "timingType": {  
        "codeId": "Code_41",  
        "code": "C99901x1",  
        "codeSystem": "http://www.cdisc.org",  
        "codeSystemVersion": "2022-12-16",  
        "decode": "After"  
    },  
    "timingValue": "P3D",  
    "timingDescription": "3 Days",  
    "timingRelativeToFrom": {  
        "codeId": "Code_44",  
        "code": "C99900x1",  
        "codeSystem": "http://www.cdisc.org",  
        "codeSystemVersion": "2022-12-16",  
        "decode": "Start to Start"  
    },  
    "relativeFromScheduledInstanceId": "ScheduledActivityInstance_3",  
    "relativeToScheduledInstanceId": "ScheduledActivityInstance_2",  
    "timingWindowLower": "PT12H",  
    "timingWindowUpper": "PT12H",  
    "timingWindow": "12..12 Hours"  
}
```

Note that the C codes yet to be allocated so "C99901xN" are example codes. Will be allocated for September 2023 CT Release




Branching

Basics

- Uses the Decision Instance
- Defined as a switch
- A set of (condition, destination) pairs
- A default link (if no condition is met)

Github Example


See JSON examples
[main branch](#)
[v14.2 branch](#)



Profile

Basics

- Uses the timeline pattern
- Reusable
- Linked to an activity or timeline



CDW Operations Metadata Management

Trial Flowchart Trial ID: CDISC360-2 Assessments: All Non-defined Defined Workflows: 119 Activities: 100 Calculators: 1



CDW Attributes: V1 V2 V3 V4 V5 V6 V7 V8 V9 V10 Last > xx

Assessments	V1	V2	V3	V4	V5	V6	V7	V8	V9	V10
Demographic	X	X	X	X	X	X	X	X	X	X
Physical status	X	X	X	X	X	X	X	X	X	X
Concomitant medication	X	X	X	X	X	X	X	X	X	X
Directions of Dosage	X	X	X	X	X	X	X	X	X	X
Demographics	X	X	X	X	X	X	X	X	X	X
Height	X	X	X	X	X	X	X	X	X	X
Weight	X	X	X	X	X	X	X	X	X	X
INCLUSION CRITERIA	X	X	X	X	X	X	X	X	X	X
EXCLUSION CRITERIA	X	X	X	X	X	X	X	X	X	X
Protocol Criteria	X	X	X	X	X	X	X	X	X	X
Other exclusion criteria	X	X	X	X	X	X	X	X	X	X
SAFETY	X	X	X	X	X	X	X	X	X	X
Adverse Events	X	X	X	X	X	X	X	X	X	X
Adverse Event Reporting	X	X	X	X	X	X	X	X	X	X
Reporting Adverse Events	X	X	X	X	X	X	X	X	X	X
Therapeutic	X	X	X	X	X	X	X	X	X	X
Other	X	X	X	X	X	X	X	X	X	X
Other Concomitant Medication	X	X	X	X	X	X	X	X	X	X
Other Demographic	X	X	X	X	X	X	X	X	X	X
Other Physical Status	X	X	X	X	X	X	X	X	X	X
Other Protocol Criteria	X	X	X	X	X	X	X	X	X	X
Other Inclusion Criteria	X	X	X	X	X	X	X	X	X	X
Other Exclusion Criteria	X	X	X	X	X	X	X	X	X	X
Other Safety	X	X	X	X	X	X	X	X	X	X

Trial ID: CDISC360-2 Trial Definition ID: CTR Trial Metadata Version: 4 Trial Definition Status: Draft Profile Name: 9-point profile Profile Type: Sequence Profile

TIME POINT SEQUENCE	SEQUENCE TIME
1	Before breakfast
2	99 minutes after start of breakfast
3	Before lunch
4	99 minutes after start of lunch
5	Before main evening meal
6	99 min after main evening meal
7	Bedtime
8	At 04:00 A.M.
9	Before breakfast the following day

Add Time Point Delete Time Point Save



Github Example

See JSON examples
[main_branch](#)
[v14.2_branch](#)


Unscheduled

Basics

- Each potential unscheduled event handled as a timeline
- One main path
- Several child paths for unscheduled events
- A condition for each
- As many instances and timing as needed
- Linked to activities, encounters as needed
- Some instances need not be linked to encounters

Examples Being Worked On


Example needed, similar to profile but an example will be provided



Cycles

Basics

- One mechanism for implementing cycles
- Other patterns could be implemented



USDM Examples I

Test Utility

- Developing a test utility:
 - Multi-sheet Excel file containing a full USDM definition (bar one or two pieces)
 - Intended to build the full USDM JSON
 - Also builds a visualisation
- Will be available as a python package

Github Examples

See JSON examples
[main branch](#)
[v14.2 branch](#)

A screenshot of a GitHub repository interface. The repository name is 'DDI-RA/Develables/IO/examples/'. The tree view shows several JSON files under the 'examples' directory, including 'Roche_Phase_3_NCT04329579.json', 'Roche_Phase_3_NCT04329515.png', 'Roche_Phase_3_NCT04329515.xlsx', 'simple.json', 'simple_1.json', 'simple_1.png', 'simple_1.xlsx', 'simple_2.json', 'simple_2.png', 'simple_2.xlsx', and 'profile.json'. Each file has a timestamp indicating it was updated 6 minutes ago.

Note



- No BC category example as yet

Current Examples

- A Roche Study
- CDISC Pilot Study
- Eli Lilly Study
- Others
 - Simple example
 - Cycle example
 - Profile example


Epoch Cycle	Screening	Baseline	Treatment		Follow-Up
First Cycle Start	-	-	-	-	-
Cycle Period	-	-	-	-	-
Cycle End Rule	-	-	-	-	-
Timing	N: 0..2 Days	N: Pre Dose	A:	P: +24 Hours	P: +7 Days
Visit Label	Screening	Baseline	15 min	Day 24	Day 35
Visit Window		0..4 Hours	0..1 Hours		-3..3 Days

Parent Activity	Child Activity	BC/Profile
-	Demographics	BC:Age, BC:Sex, BC:Race
-	Something Else	-



```
1 {  
2   "studyId": null,  
3   "studyTitle": "Simple Test 1",  
4   "studyVersion": "1",  
5   "studyType": {  
6     "codeId": "Code_1",  
7     "code": "C98388",  
8     "codeSystem": "http://www.cdisc.org",  
9     "codeSystemVersion": "2022-12-16",  
10    "decode": "Interventional Study"  
11  },  
12  "studyPhase": {  
13    "aliasCodeId": "AliasCode_1",  
14    "standardCode": {  
15      "codeId": "Code_2",  
16      "code": "C15602",  
17      "codeSystem": "http://www.cdisc.org",  
18      "codeSystemVersion": "2022-12-16",  
19      "decode": "Phase III Trial"  
20    },  
21    "standardCodeAliases": []  
22  },  
23  "businessTherapeuticAreas": [ ],  
24  "studyIdentifiers": [ ],  
25  "studyProtocolVersions": [ ],  
26  "studyDesigns": [ ],  
27  "studyRationale": "A simple test",  
28  "studyAcronym": "SIMPLE"  
29 }
```

USDM Examples II



Visualise Examples

Useful JSON tool, [JSON Crack Editor](#)

Online Utility

- Useful visualisation
- Does NOT do cross references

Web Version

Online conversion [tool here](#).

The screenshot shows a web-based utility for converting USDM Excel files to JSON. It includes a file list, upload functionality, and a status bar.

Excel File List
A list of files held within the system for which a converted USDM JSON file can be downloaded.

File List
List of files:

- Roche Phase 3 NCT04320615.xlsx, dated 2023-04-14
- cycles_1.xlsx, dated 2023-04-14
- simple_3.xlsx, dated 2023-04-14

Upload New Excel File
CLICK TO UPLOAD NEW FILE

STATUS

Online Utility

- Saves installing any software
- Will upload Excel file and return JSON equivalent
- No login as yet but will be added

USDM Examples III

USDM Excel Sheet Formats & Links Infographic

1st May 2023

Details the excel workbook format as used by the USDM python package.

Details of the package can be found at <https://github.com/date4/knowledge/usdm>.

Details for using the package and the sheet formats are detailed within the readme file within the repository.

All sheets are required to be present within the workbook and sheets are read automatically by the package. The diagrams are here to show the cross sheet references/links to aid in the assembly of study designs.

study Sheet									
1	StudyId	Sample Test 1	C	D	E	F	G	H	I
2	StudyVersion								
3	StudyType	International Study							
4	StudyKeywords	CDM2							
5	StudyDesigns	SAMPLE							
6	StudyProtocol	A protocol							
7	StudyPartners	SPONSOR: VAC-Vaccines Group, SPONSOR: REG-Regulatory							
8	StudyTitle	officialTitle	publicTitle	scientificTitle	protocolVersion	protocolAmendment	protocolEffectiveDate	protocolStatus	
9	StudyBrief	Something Official	Something Public	Something Clever	1	01/01/2010	enct	draft	
10	StudyBrief	Something Very Official	Something Public	Something Clever But Nice	1	01/01/2011	enct	draft	
11	StudyBrief	Something Very Official	Something Public	Something Clever	1	01/01/2011	enct	draft	
12	StudyBrief	Something Very Official	Something Public	Something Clever But Nice	1	01/01/2011	enct	draft	

studyDesign Sheet				
The timeline names entered in this sheet are the names of the sheets in the assembly.				
1	studyDesignProcedure	Procedure 1		
2	therapeuticProcedures	Therapeutic procedure 1, DMARDs, DMARDs-Typ 2 Diabetes, SMDM0109-Diabetic		
3	studyDesignInterventions	Intervention 1		
4	studyDesignInterventions	Basic intervention		
5	studyDesignInterventions	Intervention 2		
6	studyDesignInterventions	Intervention 3		
7	interventionTypes	PHARMACEUTICAL, DEVICE/HUMANITY		
8	interventionTypes	PHARMACEUTICAL, DEVICE/HUMANITY		
9	interventionTypes	PHARMACEUTICAL, DEVICE/HUMANITY		
10	interventionTypes	Intervention		
11	interventionTypes	Intervention		
12	interventionTypes	Intervention		
13	interventionTypes	Intervention		
14	interventionTypes	Intervention		

studyDesignEpochs Sheet				
The epoch names in the high level definitions are the epoch definitions in the studyDesigns sheet.				
1	studyEpochName	Screening	Baseline	Follow-up
2	studyEpochName	R1	R1	R1
3	studyEpochName	R2	R2	R3
4	studyEpochName	R3	R3	R4
5	studyEpochName	R4	R4	R5
6	studyEpochName	R5	R5	R6

studyDesignArms Sheet				
The arm names in the high level definitions are the arm definitions in the studyDesigns sheet.				
1	arm	Active Substance	Active Comparator Arm	Data collected From subjects
2	arm	Pancreo	Placebo-Comparator Arms	Data collected From subjects
3	arm			Data Generated Within Study
4	arm			Data Generated Within Study

studyIdentifiers Sheet					
1	IdentifierScheme	IdentifierScheme	IdentifierName	IdentifierType	IdentifierAddress
2	1	CTID	Clinical Trials	Study Registry	NCI2345678
3	2	UIN	Clinical Trials	Study Registry	AP1234
4	3	DUNS	ACME Pharma	Clinical Study Sponsor	Somewhere in a city in a state (12345) PIA

studyDesignPopulations Sheet					
1	populationDescription	plannedNumberParticipants	plannedMinimumAgeParticipants	plannedMaximumAgeParticipants	plannedNumberParticipants
2	1	300	18 years	40 years	300
3	2	Pop 1	20	18 years	M
4	3	Pop 2	20	18 years	F

studyDesignEstimands Sheet

studyDesignEstimands Sheet					
1	used	populationDescription	interventionTermination	interventionTermination	interventionTermination
2	1	EST1	Survival of patients	ITT	ITT
3	2	EST2	Real staff	IC Event Description Number 1	IC Event Description Number 2
4	3	EST3	Something else	IM2	EN2

studyDesign1 Sheet

studyDesign1 Sheet		
1	type	description
2	2	IM2
3	3	An Intervention
4	4	An Intervention
5	5	An Intervention

Timeline names Sheet						
1	Name	Main Timeline Description	Epoch Cycle	Screening	Baseline	Treatment
2		The timeline names entered in this sheet are the names of the sheets in the assembly.	-	-	-	-
3	Condition	Potential subject identified	First Cycle Start	Cycle Period	Timing	Follow-up
4			N: 0 Days	E1	N: Pre Date	A: 24 hours
5			E2	A: Follow	E3	P: +7 Days
6					E4	E: 3 Days
7						
8	Event Activity	Ch-M Activity	IC/Procedure/Timeline			
9	-	-	IC-Preop, BC-Sex, BC-Race, BC-Body Weight	X		
10	-	-	Something Else	X	X	X

studyDesignElements Sheet

studyDesignElements Sheet					
1	used	studyElementName	studyElementDescription	studyElementType	studyElementSetting
2	1	EL1	Screening Element	Screened	Clinic
3	2	EL2	Treatment Element 1	Not Administered	In Person
4	3	EL3	Follow Up Element	Treated	Telephone
5	4	EL4	Treatment Element 2	Not Administered	At Home

studyDesignEncounters Sheet					
1	encounterName	encounterType	encounterDuration	encounterEnvironmentSetting	encounterConditionsNotes
2	1	EE1	1 week	Screening encounter	Visits
3	2	EE2	2 days	Baseline encounter	Visits
4	3	EE3	5 days	1 week visit	Visits
5	4	EE4	Day 15	Day 15	HOME

studyDesignProcedures Sheet

studyDesignProcedures Sheet					
1	used	procedureName	procedureDescription	procedureCode	procedureConfidential
2	1	TE1	Test 1	SNOMED_12345678-Test	Y
3	2	TE2	Test 2	SNOMED_12345678-Test	Only do it they have no Rx

Infographic

Download high resolution [version here](#)
Further info will be added

Conformance & Rules

Class	Attributes (Generic names)	Rules
StudyDesign, StudyEpoch, Encounter, ScheduleTimeline, Activity, Procedure, BiomedicalConceptSurrogate, BiomedicalConceptCategory	Name and Description attributes	Name should always be present but Description is optional
Activity, Procedure	Conditional and ConditionalReason	If Conditional is true then Reason must be present. If false then reason should be ignored
Timing	timingWindow, timingWindowLower, timingWindowUpper	If timing window present then Lower and Upper should be present
	From To	For anchor then To does not need to be set or could be set the same as From
ScheduledInstance	defaultConditionId, scheduleTimelineExitId	Only one should be set. Generally default is set, but if Exit is set then no default.

Work In Progress
Starting to think of the more complex, cross-field, "rules"

Look to implement as CORE rules

This will be part of Phase 3